X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs VENUS REMEDIES - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. VENUS REMEDIES WOCKHARDT LTD./
VENUS REMEDIES
 
P/E (TTM) x -12.1 -9.9 - View Chart
P/BV x 2.4 0.2 1,574.0% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 WOCKHARDT LTD.   VENUS REMEDIES
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
VENUS REMEDIES
Mar-17
WOCKHARDT LTD./
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,129143 790.6%   
Low Rs62765 964.6%   
Sales per share (Unadj.) Rs363.1324.2 112.0%  
Earnings per share (Unadj.) Rs-20.46.4 -319.0%  
Cash flow per share (Unadj.) Rs-7.040.6 -17.2%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs301.8366.0 82.5%  
Shares outstanding (eoy) m110.5512.34 895.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.40.3 754.4%   
Avg P/E ratio x-42.916.2 -264.9%  
P/CF ratio (eoy) x-125.92.6 -4,915.7%  
Price / Book Value ratio x2.90.3 1,024.6%  
Dividend payout %-48.90-   
Avg Mkt Cap Rs m97,0631,282 7,570.5%   
No. of employees `0006.80.9 749.5%   
Total wages/salary Rs m9,665251 3,850.6%   
Avg. sales/employee Rs Th5,931.84,430.1 133.9%   
Avg. wages/employee Rs Th1,428.1278.0 513.8%   
Avg. net profit/employee Rs Th-334.087.6 -381.3%   
INCOME DATA
Net Sales Rs m40,1464,000 1,003.6%  
Other income Rs m1,14323 5,033.0%   
Total revenues Rs m41,2894,023 1,026.3%   
Gross profit Rs m128785 16.3%  
Depreciation Rs m1,489422 353.2%   
Interest Rs m2,253344 655.4%   
Profit before tax Rs m-2,47242 -5,870.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-211-37 570.5%   
Profit after tax Rs m-2,26079 -2,857.6%  
Gross profit margin %0.319.6 1.6%  
Effective tax rate %8.5-87.9 -9.7%   
Net profit margin %-5.62.0 -284.8%  
BALANCE SHEET DATA
Current assets Rs m46,1602,606 1,771.2%   
Current liabilities Rs m19,2581,980 972.5%   
Net working cap to sales %67.015.6 428.3%  
Current ratio x2.41.3 182.1%  
Inventory Days Days101128 78.5%  
Debtors Days Days9443 218.0%  
Net fixed assets Rs m40,1655,353 750.3%   
Share capital Rs m553123 447.9%   
"Free" reserves Rs m32,8144,393 747.0%   
Net worth Rs m33,3674,516 738.9%   
Long term debt Rs m31,9031,618 1,971.5%   
Total assets Rs m89,6878,291 1,081.7%  
Interest coverage x-0.11.1 -8.7%   
Debt to equity ratio x1.00.4 266.8%  
Sales to assets ratio x0.40.5 92.8%   
Return on assets %05.1 -0.2%  
Return on equity %-6.81.8 -386.8%  
Return on capital %-0.36.3 -5.3%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m9,1210-   
Fx outflow Rs m2,133736 289.7%   
Net fx Rs m6,988-736 -949.0%   
CASH FLOW
From Operations Rs m-2,695997 -270.2%  
From Investments Rs m-6,863-461 1,487.7%  
From Financial Activity Rs m12,545-571 -2,197.0%  
Net Cashflow Rs m3,010-35 -8,576.4%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.2 1,277.8%  
FIIs % 7.7 0.6 1,327.6%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 66.4 23.2%  
Shareholders   67,757 20,121 336.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  SANOFI INDIA  ALKEM LABORATORIES  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jun 15, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS